chrisvoncsefalvay/vaers-outcomes huggingface dataset:
HEART PALPITATION; MUSCLES SPASM IN RIGHT ARM; BODY ACHE; INJECTION SITE ARM SORENESS; MILD FATIGUE; STOMACH UPSET; TWITCHING IN RIGHT ARM; This spontaneous report received from a patient concerned a 41 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included penicillin allergy.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1808609, expiry: UNKNOWN) dose was not reported, administered on 20-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 20-MAR-2021, the subject experienced stomach upset. On 20-MAR-2021, the subject experienced twitching in right arm. On 20-MAR-2021, the subject experienced muscles spasm in right arm. On 20-MAR-2021, the subject experienced body ache. On 20-MAR-2021, the subject experienced injection site arm soreness. On 20-MAR-2021, the subject experienced mild fatigue. On 03-APR-2021, the subject experienced heart palpitation. On 12-APR-2021, Laboratory data included: Blood test (NR: not provided) Normal, and Electrocardiogram (NR: not provided) Normal. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from stomach upset, body ache, injection site arm soreness, and mild fatigue on 23-MAR-2021, and was recovering from twitching in right arm, heart palpitation, and muscles spasm in right arm. This report was non-serious.
One week after 2nd dose I began experiencing dizziness when getting up from a probe position. I have had EKG, glucose test, complete blood workup, metabolic panel and MRI. No cause was determined. Today is 20 days after vaccine and symptoms persist. I have appt Monday, 3/29, with audiologist to see if there is an inner ear problem
Symptoms:  Sensation of lump in left side of throat.  No issues with swallowing nor breathing.  Has had multiple allergic reactions before and never presented this way.  No rash, no dizziness as has experienced.  Does not feel this is an allergic reaction.    PE: Nontoxic and very well appearing, speaking clearly in NAD.  Clear and patent oropharynx.  No respiratory distress.   Treatment:  Observed for an hour, no change in mild sensation of left sided lump in throat.  Declined 911 transfer.  Patient has his own EpiPen with him in the car and wanted to go home and will take antihistamines when home and aware if he uses the EpiPen will call 911.  Family member drove home.
Breakthrough Covid-19 Hospitalization  ER Triage Note    a 68 year old FEMALE presents to Emergency   Department on 12/02/21 10:59.         Active Inpatient Medications                           Status ========================================================================   1)   ACETAMINOPHEN TAB  2 TABLETS PO Q6H PRN FOR MILD PAIN  ACTIVE          OR FEVER. ALTERNATE WITH IBUPROFEN IF USED FOR          FEVER (max 4,000mg APAP/24hrs from all sources)   2)   APIXABAN TAB,ORAL  10MG PO Q12H                        ACTIVE   3)   ATORVASTATIN TAB  40MG PO DAILY                        ACTIVE   4)   BENZONATATE CAP,ORAL  100MG PO Q8H PRN FOR DRY COUGH   ACTIVE   5)   DEXTROSE 50% INJ,SOLN  25 GRAMS IV PUSH Q15M PRN FOR   ACTIVE          HYPOGLYCEMIA WHEN PATIENT IS UNRESPONSIVE AND          GLUCOSE IS LESS THAN 70  ***NOTIFY PHYSICIAN*** ->          REASSESS IN 15 MINUTES AND CONTINUE WITH          HYPOGLYCEMIA PROTOCOL   6)   DEXTROSE GEL,ORAL  15.5 mL (1/2 TUBE, 12 gm GLUCOSE)   ACTIVE          PO Q15M PRN FOR HYPOGLYCEMIA WHEN PATIENT IS          RESPONSIVE AND GLUCOSE IS 50-70  -> REASSESS IN 15          MINUTES AND CONTINUE WITH HYPOGLYCEMIA PROTOCOL   7)   DEXTROSE GEL,ORAL  31 mL (1 TUBE, 24 gm GLUCOSE) PO    ACTIVE          Q15M PRN FOR HYPOGLYCEMIA WHEN PATIENT IS          RESPONSIVE AND GLUCOSE IS LESS THAN 50 ***NOTIFY          PHYSICIAN*** -> REASSESS IN 15 MINUTES AND CONTINUE          WITH HYPOGLYCEMIA PROTOCOL   8)   ELECTROLYTE POWDER,ORAL  1 PACKET IN 1 QUART OF WATER  ACTIVE          AND DRINK PO BID PRN FOR DIARRHEA   9)   FAMOTIDINE TAB  20MG PO HS                             ACTIVE   10)  GLUCAGON INJ  1MG/1VIAL IM ONCE PRN FOR HYPOGLYCEMIA   ACTIVE          WHEN PATIENT UNRESPONSIVE AND NO IV ACCESS          ***NOTIFY  PHYSICIAN*** -> REASSESS IN 15 MINUTES          AND CONTINUE WITH HYPOGLYCEMIA PROTOCOL.          SUBCUTANEOUS ALLOWED.   11)  INSULIN ASPART INJ  CORRECTIONAL PROTOCOL SQ HS BG     ACTIVE          <70=PROTOCOL; 70-175=0 UNIT; 176-200=1 UNIT;          201-225=2 UNITS; 226-250=3 UNITS; 251-300=4 UNITS;          301-350=5 UNITS; 351-400=6 UNITS; >400=7 UNITS   12)  INSULIN ASPART INJ  MILD CORRECTIONAL PROTOCOL SQ      ACTIVE          WITH MEALS BG <70=PROTOCOL; 71-150=0 UNIT;          151-175=1 UNIT; 176-200=2 UNITS; 201-225=3UNITS;          226-250=4 UNITS; 251-300=6 UNITS; 301-350=8 UNITS;          351-400=10 UNITS; >400=12 UNITS   13)  INSULIN GLARGINE PREFILLED PEN INJ  18 UNITS SQ QDAY   ACTIVE   14)  LOSARTAN TAB  25MG PO DAILY HOLD FOR SBP less than     ACTIVE          135   15)  METOPROLOL TARTRATE (IR) TAB  12.5MG PO BID hold for   ACTIVE          sbp less than 130 or HR less than 60   16)  ONDANSETRON TAB,ORAL DISINTEGRATING  4MG ODT BID PRN   ACTIVE          PRN FNV   17)  REMDESIVIR INJ REMDESIVIR 100 MG in SODIUM CHLORIDE    ACTIVE          0.9% 100 ML  INFUSE OVER 30 Minutes IVPB Q24H   18)  guaiFENesin TAB  ONE (1) TABLET PO Q4H PRN FOR WET     ACTIVE          COUGH   Patient is being discharged from HOSPITAL  Care Unit today DEC 08, 2021
fever 104-105, rash on stomach, swelling in neck; lump behind rt ear; lasted 2-3 days; MD ordered Duricef & Advil;
Provider d/c note:  "89 YO female with history of sacral decubitus ulcer stage IV, dementia, dm 2, recent prolonged hospitalization due to septic shock from infected sacral decubitus ulcer presented from a residential facility due to concern for weakness.  She was found to be COVID positive as well.  She was subsequently admitted for management of failure to thrive and sepsis due to sacral wound ulcer and action.   During her hospitalization stay, patient started on vancomycin and Zosyn.  Surgical team consulted and perform bedside debridement of sacral wound ulcer.  It was noted that the sacral wound is extensive.  Surgeon who performed debridement shared that prognosis is likely grave.  Her hospitalization is further complicated by vancomycin resistant Enterococcus faecium and Staphylococcus epidermis bacteremia with likely sources in her urine and sacral ulcer.  Antibiotics transition to ampicillin, cefepime and Flagyl.  Due to poor overall prognosis, patient was transitioned to hospice after discussion with patient's son who is also POA. He chose for his mother to go back to the residential facility under hospice care.  Abx disccontinued and patient transfer back to residential facility. "
I was positive for COVID-19 on 31JAN2023, I was very tired and fatigued. I was prescribed PAXLOVID, then I started to feel sick few days after like I had a rebound. I was really stuffed up with my sinuses for 3 days.
She was losing her balance and some of her speech was not coming out right. She woke up and her right eye vision was completely black and is blind in the right eye. Went to the doctor for her eye, they did a run tests and the tests showed that the frontal lobe of her brain showed lesions. They saw it by using contrast. They said it could be early dementia or Alzheimer's or MS.  They gave her a heart monitor. She also can put a large magnet on her arm and chest and it stays.
Developed a DVT in Right Leg; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 50-year-old female patient received BNT162b2 (BNT162B2), in Apr2021 as dose 2, single (Batch/Lot number: unknown) at the age of 50 years, in right arm for covid-19 immunisation. The patient's relevant medical history included: "DVT in Right Leg", start date: Jan2021 (unspecified if ongoing), notes: Dates when patient was in hospital for Developed a DVT in Right Leg: Jan2021 to Jan2021. There were no concomitant medications. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE, Time: Not Provided , Anatomical Site of injection: Right Arm , Route of Administration: Not Provided), administration date: Mar2021, when the patient was 49 years old, for COVID-19 immunization. The following information was reported: DEEP VEIN THROMBOSIS (hospitalization, medically significant) with onset Jan2022, outcome "not recovered", described as "Developed a DVT in Right Leg". The patient was hospitalized for deep vein thrombosis (hospitalization duration: 3 day(s)). The event "developed a dvt in right leg" required emergency room visit. The patient underwent the following laboratory tests and procedures: Ultrasound scan: (Jul2022) they still see some DVT in her right leg, notes: Caller states she is still taking blood thinners and she had an ultrasound last Jul. Therapeutic measures were taken as a result of deep vein thrombosis. Clinical course: It was reported that the patient took the Covid vaccine back in 2021 and developed a DVT after patient took the vaccine. The reporter stated patient is still taking blood thinners and patient had an ultrasound last Jul, and still see some DVT in patient right leg. It was reported that patient was seen in the ER and then admitted to the hospital for 3 days. Patient received treatment with Xarelto 10mg once a Day.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Had developed 4 welts on (L) shoulder area; appeared as if hit by tree branch. 3 welts at 7 x 1cm long and one 4 x 25cm. Welts were red, raised and warm to touch. Welts were not located by inj. site but more anterior.
Information regarding Flumist (2003-2004 Formula) (influenza virus vaccine, live intranasal (2003-2004 formula) nasal solution (frozen)) was received from a consumer regarding a 36-year-old female patient who experienced flu-like symptoms. At 36 years of age, the patient received a dose on 15-Dec-2003. Medical history: The patient had no relevant medical history. She reported she does not have an egg allergy. Product details: Indication for Flumist (2003-2004 Formula) was immunization. Product was administered on 15-Dec-2003. Dose regimen was 1 dose (intranasal). Concomitant therapy: Concomitant therapy included Yasmin (drospirenone/ethinyl estradiol). Event details: The patient experienced flu-like symptoms (influenza like illness) characterized by dizziness (dizziness), weakness (asthenia) and chills (rigors) on 15-Dec-2003. She went to the emergency room but was not seen. As of 15-Dec-2003, the events had not resolved. No additional information was available at the time of this report.
I experienced the following side effects 45 minutes to 1 hour after I received the 1st administration of the Pfizer Covid19 vaccine.  The side effects ended 24 hours after I received the injection. 1- Sneezing 2- Excessive Running Nose 3- Watery Eyes
Some blood in her underwear that was a purplish color; This is a spontaneous report from a contactable consumer (patient). A 49-years-old female patient received unknown dose of bnt162b2 (BNT162B2, solution for injection) via an unspecified route of administration on 04Aug2021 (Batch/Lot number was not reported) as SINGLE for covid-19 immunization. Patient medical history in 2005, patient had hysterectomy. She had some bleeding from the incision two years ago, but no longer gets periods from an unknown date and unknown if ongoing. The patient's concomitant medications were not reported. On an unspecified date in Aug2021, It was reported that after working out on thursday patient had some blood in her underwear that was a purplish color which occurred again today and wants to know if this is a known side effect. Responded that the authorized EUA Prescribing Information for the Pfizer-BioNTech COVID-19 Vaccine does not list menstrual changes as adverse reaction from clinical studies and post authorization experience. The outcome of event was unknown.  Lot/batch number is not available despite the follow-up attempts made. Follow-up attempts have been completed and no further information is expected
No adverse effects reported; Multiple patients were vaccinated with improperly stored ROTATEQ on multiple dates; Information has been received from a medical assistant concerning a patient of unknown age, gender and race. The patient's medical history, drug allergies, previously drug reactions, concurrent conditions and concomitant medications were not reported.  On 15-APR-2019, the patient was vaccinated with an improperly stored dose of Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ) orally for prophylaxis (lot number reported as R021930 with expiration date in 18-JUN-2020) (strength and anatomical location were not provided).  The Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ) was stored at an unknown temperature for an unknown time frame. There was a previous temperature excursion and the call was because of a data logger.  No adverse effects reported.  Lot number R021930 is an invalid lot number for Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ).  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-1907USA001848: US-009507513-1907USA001849: US-009507513-1906USA011434: US-009507513-1907USA001793: US-009507513-1907USA001794: US-009507513-1907USA001795: US-009507513-1907USA001796: US-009507513-1907USA001797: US-009507513-1907USA001798: US-009507513-1907USA001799: US-009507513-1907USA001800: US-009507513-1907USA001801: US-009507513-1907USA001802: US-009507513-1907USA001803: US-009507513-1907USA001804: US-009507513-1907USA001805: US-009507513-1907USA001806: US-009507513-1907USA001807: US-009507513-1907USA001808: US-009507513-1907USA001809: US-009507513-1907USA001810: US-009507513-1907USA001811: US-009507513-1907USA001812: US-009507513-1907USA001813: US-009507513-1907USA001814: US-009507513-1907USA001815: US-009507513-1907USA001816: US-009507513-1907USA001817: US-009507513-1907USA001818: US-009507513-1907USA001819: US-009507513-1907USA001820: US-009507513-1907USA001821: US-009507513-1907USA001822: US-009507513-1907USA001823: US-009507513-1907USA001824: US-009507513-1907USA001825: US-009507513-1907USA001826: US-009507513-1907USA001827: US-009507513-1907USA001828: US-009507513-1907USA001829: US-009507513-1907USA001830: US-009507513-1907USA001831: US-009507513-1907USA001832: US-009507513-1907USA001833: US-009507513-1907USA001834: US-009507513-1907USA001835: US-009507513-1907USA001837: US-009507513-1907USA001838: US-009507513-1907USA001839: US-009507513-1907USA001840: US-009507513-1907USA001841: US-009507513-1907USA001842: US-009507513-1907USA001843: US-009507513-1907USA001844: US-009507513-1907USA001845: US-009507513-1907USA001846: US-009507513-1907USA001847: US-009507513-1907USA000952: US-009507513-1907USA000989: US-009507513-1907USA000962: US-009507513-1907USA000988: US-009507513-1907USA000963: US-009507513-1907USA000953: US-009507513-1907USA000959: US-009507513-1907USA000968: US-009507513-1907USA000967: US-009507513-1907USA000964: US-009507513-1907USA000966: US-009507513-1907USA000954: US-009507513-1907USA000969: US-009507513-1907USA000970: US-009507513-1907USA000965:
Non-stop crying.  Unwillingness to eat. Legs (where vaccinated) are extremely sensitive to touch.
Flu symptoms ( headaches, body aches , fever) for. 3 + days.  Day 4 petechiae on chest, back, right breast. 5th day bruising stomach and calf muscle and petechiae on stomach. Contacted primary doctor and sent for CBC on 4/14/2021. Not sure if side effect but thought it should be reported
Supra-ventricular Tachycardia; This case was reported by a pharmacist via call center representative and described the occurrence of supraventricular tachycardia in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix at an unknown dose. On an unknown date, less than 2 years after receiving Shingrix, the patient experienced supraventricular tachycardia. On an unknown date, the outcome of the supraventricular tachycardia was unknown.   It was unknown if the reporter considered the supraventricular tachycardia to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The age group was not reported but was selected as per the vaccine indication. The reporter stated that, the patient experienced supraventricular tachycardia after receiving Shingrix. The reporter did not consent to follow up. The reporter declined to provide details.
Facial numbness, swelling and hives all over neck.  Brain fog.   The symptoms left on March 25th.  Facial numbness & brain fog have returned today March 26th
On 10/10/2022 I was having chest congestion, cough, sneezing, and sore throat. On 10/12/2022 I went to an urgent care and had a rapid test and it was negative. On 10/16/2022 I took a home test and the results were positive. My symptoms were about the same. On 10/17/2022, I did telemedicine and the doctor prescribed prednisone, and the reason was I had a medication, alfuzosin, that was counter to the antibodies. That is why they did not prescribe the PAXLOVID. I have had a negative test, but I still do not feel 100 percent. I still have a cough.
Vaccinated - 4pm 11/11. Awakened with swollen lips next couple mornings. Lips painful, irritated. Started 11/12 9:30 a.m.
This is a spontaneous report from a contactable consumer or other non hcp. A 44-years-old female patient received bnt162b2 (Pfizer-BioNTech COVID-19 mRNA vaccine, Solution for injection, Batch/Lot Number: EL3249), via intramuscular route of administration, administered in Arm Left on 28Jan2021 13:30 as 2ND DOSE SINGLE for covid-19 immunisation. Patient didn't received other vaccination with in 4weeks prior to vaccination patient didn't had any illness at the time of vaccination. Medical history reported as gastritis from an unknown date and unknown if ongoing Gastritis, constipation from an unknown date and unknown if ongoing IBS with Constipation, irritable bowel syndrome from an unknown date and unknown if ongoing, abdominal discomfort from an unknown date and unknown if ongoing, anxiety from an unknown date and unknown if ongoing. Concomitant medications included pantoprazole (PANTOPRAZOLE) taken for abdominal discomfort from an unspecified start date and ongoing; citalopram (CITALOPRAM) taken for abdominal discomfort from an unspecified start date and ongoing; clonazepam (CLONAZEPAM) taken for anxiety from an unspecified start date and ongoing. The patient underwent lab tests and procedures which included blood pressure measurement low on 11Feb2021, blood prolactin 62.1 ng/ml on 27Jan2021, body temperature 103 on spiked to 101 on 28Jan2021, then went up to about 103 for the next few days. States that it has improved but has levelled out to be a constant 100-100.5. This morning her temperature was 100.9, body temperature: 101 on 28Jan2021 spiked to 101 on 28Jan2021, then went up to about 103 for the next few days. States that it has improved but has levelled out to be a constant 100-100.5. This morning her temperature was 100.9, chest x-ray: normal on 11Feb2021, electrocardiogram normal on 11Feb2021, sars-cov-2 test: negative on 11Feb2021, sars-cov-2 test: negative on 17Feb2021, scan brain: unknown results on unspecified date. The patient experienced low grade fever on 28Jan2021, headache on 29Jan2021, sweats on 29Jan2021, chills on 29Jan2021, diarrhoea on an unspecified date, body aches on 29Jan2021, breast lactation on Jan2021, low blood pressure on 11Feb2021, breast pain on Jan 2021, dizziness on 11Feb2021, joint pain on 29Jan2021 patient was required to visit the emergency room for the events dizziness and hypotension. Therapeutic measures were taken as a result of, body aches (pain), low blood pressure (hypotension), joint pain (arthralgia). The outcome of the events hyperhidrosis, chills was unknown pyrexia, headache, Arthralgia,pain was recovering, diarrhoea, galactorrhoea,breast pain was not recovered, dizziness and hypotension was recovered on 11 Feb 2021. Follow-up attempts completed. No further information expected.
Low Grade Fever/ 100F and lower; Bad Headache/ Intense headache varying in intensity; Chills off and on throughout day; Lack of appetite; weakness; Nausea/ Intense nausea. One instance of vomit; This spontaneous case was reported by a consumer and describes the occurrence of DECREASED APPETITE, ASTHENIA (weakness), NAUSEA, PYREXIA (Low Grade Fever / 100F and lower), and HEADACHE (Intense headache varying in intensity) in a 72-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 042L20A and 025L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history information was reported.  Concomitant products included B-12 and VITAMIN D 2000 for an unknown indication.   On 05-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 03-Feb-2021, the patient experienced DECREASED APPETITE, ASTHENIA (weakness), NAUSEA, HEADACHE (Intense headache varying in intensity), and CHILLS. On an unknown date, the patient experienced PYREXIA (Low Grade Fever/ 100F and lower). At the time of the report, DECREASED APPETITE, ASTHENIA (weakness), NAUSEA, PYREXIA (Low Grade Fever/ 100F and lower), HEADACHE (Intense headache varying in intensity), and CHILLS outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In February 2021, Body temperature: 100f (normal) 100F.         The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was considered to be not applicable.  No treatment medications were provided.   Most recent FOLLOW-UP information incorporated above includes: On 19-Apr-2021: Patient demographics, lab data, and concomitant medications were updated. Two events were added (chills and loss of appetite). On 19-Apr-2021: additional information received on 19-APR-2021 and does not contain any new information
PATIENT REPORTED PAIN, FEVER, AND MUSCLE SPASM. MUSCLE SPASM DEVELOPED THE DAY AFTER INJECTION AND PAIN NOT RESOLVED WITH OVER THE COUNTER PAIN MEDS (IBUPROFEN).
because of having Bronchitis that she got recently after she took 1st dose.; This is a spontaneous report from a Pfizer Sponsored Program a contactable consumer or other non hcp(patient). A female patient of an unspecified age received bnt162b2 (CONMINTARY, Solution for injection, Lot No: was not reported), via an unspecified route of administration on 09Mar2021 as 1stdose, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported.  The patient experienced because of having bronchitis that she got recently after she took 1st dose on Mar2021. Patient was advised by her doctor that don't take the 2nd dose vaccine be-cause of having Bronchitis that she got recently after she took 1st dose.Outcome of the event was unknown.    No follow-up attempts are possible; information about lot/batch number cannot be obtained.
pt recvd vax & exp edema of the upper arm from inject site to the elbow, redness & heat; pt was treated w/Dicloxacillin, Motrin, & moist heat;